Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy of dotinurad in lowering serum uric acid sUA levels in adults with gout who cannot tolerate xanthine oxidase inhibitors XOI or have failed uricase treatment. This Phase 2, randomized, double-blind, placebo-controlled study focuses on participants aged 18 to 75 with gout diagnosed for at least one year, assessing dotinurads ability to reduce sUA by Week 24. Participants are assigned to one of two groups one group receives dotinurad for 36 weeks, divided into a 24-week initial treatment period followed by a 12-week continuation. The other group takes placebo for the first 24 weeks and then switches to dotinurad for the final 12 weeks. Dotinurad is given orally as over-encapsulated tablets, while placebo capsules contain microcrystalline cellulose. This design allows comparison of dotinurad with placebo before all participants receive the active drug. During the study, participants undergo regular assessments including serum uric acid measurements at various timepoints up to Week 40. Researchers monitor the percentage of participants achieving target sUA levels, changes from baseline sUA, and treatment-emergent adverse events. Female participants of childbearing potential must have pregnancy tests and follow contraception requirements. The trial is expected to complete by August 2027, providing detailed safety and efficacy data over the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the efficacy and safety of enpatoran in adults aged 18 to 75 with active cutaneous manifestations of lupus erythematosus, either with or without systemic disease. This global, multicenter Phase 3 study aims to understand how enpatoran works compared to a placebo in addition to standard care over a 24-week treatment period. The study is sponsored by EMD Serono Research & Development Institute, Inc. and includes participants diagnosed with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, andor Acute Cutaneous Lupus Erythematosus, with or without systemic lupus erythematosus. Participants are randomly assigned to receive either enpatoran tablets or matching placebo tablets taken orally twice daily for 24 weeks while continuing their standard of care treatments. The study intervention is administered as film-coated tablets, and participants are monitored throughout the treatment period. Visits occur every four weeks, with a televisit at Week 2, allowing ongoing assessment of the participants condition and response to treatment. Throughout the study, participants undergo regular evaluations including the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other measures of lupus activity and symptom changes. Researchers monitor for treatment-emergent adverse events, serious adverse events, and laboratory abnormalities from Day 1 to Week 24. The primary outcome is the percentage of participants achieving a 70% or greater reduction in CLASI-A score at Week 24. Total study participation can last up to 35 weeks, including screening and follow-up assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.
Actively Recruiting
Researchers are evaluating sarilumab, given at two different doses, for treating adults aged 50 years and older with early polymyalgia rheumatica PMR. This randomized, double-blind, placebo-controlled Phase 3 study aims to compare the effectiveness of sarilumab plus a 52-week prednisone taper against placebo plus the same prednisone taper. The purpose is to assess whether sarilumab can improve sustained remission rates and to determine its safety and tolerability in this population. Participants are assigned to one of three groups placebo with prednisone taper, sarilumab 150 mg every two weeks with prednisone taper, or sarilumab 200 mg every two weeks with prednisone taper. The prednisone taper lasts 52 weeks. The study includes an initial screening visit, baseline and randomization visit with first drug administration, multiple treatment visits every two weeks from Week 2 to Week 44, an end of treatment visit at Week 52, and a final study visit at Week 58. During the study, participants will undergo regular assessments including monitoring for remission status, flare rates, and changes in PMR activity scores. Safety will be evaluated by tracking adverse events, laboratory values, and antibody formation against the drug throughout the study period up to Week 58. Participants may also complete quality of life questionnaires during the study. The total participation time spans approximately 58 weeks.
Actively Recruiting
Researchers are evaluating afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8, to see if it can improve skin disease in adults with active cutaneous lupus erythematosus CLE, with or without systemic lupus. This study focuses on adults whose disease has not responded to or who cannot tolerate antimalarial therapy. The trial is conducted in two stages under a single protocol to assess efficacy and safety. Participants are randomly assigned to receive one of two doses of afimetoran or a matching placebo capsule once daily for 24 weeks alongside their existing lupus care during the first stage. The second stage compares the chosen afimetoran dose to placebo to confirm results. After the 24-week placebo-controlled period, all participants receive afimetoran for an additional 28 weeks, totaling 52 weeks of treatment. During the study, researchers monitor changes in skin disease activity using the CLASI-A score and the percentage of participants achieving at least a 70% improvement at Week 24. Additional assessments include patient quality of life measures, lupus disease activity, and safety monitoring for adverse events up to 52 weeks. Participants follow study requirements including contraception protocols and regular evaluations throughout the trial.